| Description |
1 online resource (359 pages) : illustrations (some colors). |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
Cancer etiology, diagnosis, and treatments |
|
Cancer etiology, diagnosis, and treatments.
|
| Bibliography |
Includes bibliographical references and index. |
| Note |
Print version record. |
| Contents |
CHRONIC MYELOID LEUKEMIA: FROM DAILY MANAGEMENT TO COMPLICATED ISSUES; Library of Congress Cataloging-in-Publication Data; Contents; Preface; In Memorium; Section I; Chapter I: Definition, Epidemiology, Natural History and Clinical Phases; Abstract; Introduction; Epidemiology; Risk Factors; Natural History; Clinical Phases; References; Section II; Chapter II: CML: Clinical Diagnosis, Differential Diagnosis and Scoring Systems; Abstract; Introduction; CML Scoring Systems of Disease Prognosis; Differential Diagnosis of CML; References. |
|
Chapter III: Chronic Myelogenous Leukemia, Morphology and ImmunophenotypeAbstract; Introduction; Chronic Phase; Accelerated Phase; Blast Crisis; Differential Diagnoses; Flow Cytometric Immunophenotyping; Conclusion; References; Chapter IV: Cytogenetic and Molecular Aspects of CML; Abstract; Introduction; Molecular Basis of CML; Cytogenetic and Molecular Testing Methods; Cytogenetic Findings in CML; Cytogenetic and Molecular Testing; Diagnosis; Minimal Residual Disease Monitoring; TKI Resistance Testing; Conclusion; References; Chapter V: Molecular Mechanisms in CML Pathogenesis; Abstract. |
|
IntroductionThe BCR-ABL Oncogene; BCR-ABL Causes Aberrant Signaling in CML; Changes in Telomeres and Telomerases in CML; Genetic Alterations in CML; Pathogenesis of Transformation; The CML Stem Cell; References; Chapter VI: Secondary Resistance to Tyrosine Kinase Inhibitors: Focus on Molecular Mechanisms other than BCR-ABL Overexpression and Mutations; Abstract; Introduction; 1. Drug Transporters; 2. Signalling Pathways Included in CML Resistance to TKIs -- Towards "BCR-ABLIndependence""; 3. Role of Multifunctional (proto-)oncogenes and Tumor Suppressors in CML Resistance to TKIs. |
|
4. Programmed Cell Death Capacity of CML Cells -Autophagic Cell Death and Responsiveness to Imatinib (TKIs)5. Mitochondria and Metabolism in CML Cells; 6. Sensitivity of Primitive CD34+ CML Cells to Tyrosine Kinase Inhibitors; Summary and Discussion; References; Section III; Chapter VII: Frontline Therapy; Abstract; Introduction; Pathophysiology of CML; Management of CML; Pharmacotherapy for CML; Monitoring Treatment Response; Monitoring for Minimal Residual Disease (MRD); Improving Treatment Outcomes in the Frontline Setting; TKIs -- Fertility and Pregnancy; Conclusion; References. |
|
Chapter VIII: Management of Tyrosine Kinase Inhibitors ResistanceAbstract; Introduction; Defining Lack of Response to TKI Therapy and Treatment Failure; Pathophysiology and Causes of Treatment Failure; Primary Resistance; BCR-ABL Dependent Mechanisms; BCR-ABL-Independent Mechanisms of Resistance; Molecular Monitoring for Resistance; Management of TKI Resistance; Third Line Therapy; Newer Therapies; Role of HSCT; References; Chapter IX: Management of Chronic Myeloid Leukemia (CML): Accelerated Phase(AP); Abstract; Introduction; Accelerated Phase: Diagnostic Criteria. |
| Subject |
Chronic myeloid leukemia.
|
|
Blood -- Diseases.
|
|
Cancer.
|
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
|
Hematologic Diseases |
|
Neoplasms |
|
Leucémie myéloïde chronique.
|
|
Sang -- Maladies.
|
|
Cancer.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Blood -- Diseases
|
|
Cancer
|
|
Chronic myeloid leukemia
|
| Added Author |
Ustun, Celalettin.
|
|
Popat, Uday R.
|
| Other Form: |
Print version: Chronic myeloid leukemia : from daily management to complicated issues. Hauppauge, NY : Nova Science Publishers, Inc., [2014] x, 345 pages Cancer etiology, diagnosis and treatments 9781629489711 (DLC) 17961924 |
| ISBN |
9781629489926 (e-book) |
|
1629489921 (e-book) |
|
9781629489711 (hardcover) |
|
1629489719 |
| Standard No. |
AU@ 000056896546 |
|
AU@ 000065259156 |
|
